GSK-2634673F

N/A

Report date: 2025/11/20 16:01:00

Base Information

Drug NameGSK-2634673F

Drug Alias Name18F-FBA-A20FMDV2GSK263467FGSK-263467-F[18F]-FBA-A20FMDV2

ClassificationRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancersIntegrin alpha-V/beta-6 antagonists

TargetsIntegrin alpha-V/beta-6

Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsIdiopathic Pulmonary Fibrosis

Other Information

ATC CodeN/A